Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023;52(2):210-218.
doi: 10.1159/000526319. Epub 2022 Nov 2.

Anti-Inflammatory Approach in Chronic Dialysis Patients with SARS-CoV-2: ATA or PMMA Dialyzers?

Gabriele Donati  1   2 , Lorenzo Gasperoni  3 , Marianna Napoli  4   5 , Anna Scrivo  4   5 , Fulvia Zappulo  4   5 , Chiara Abenavoli  4   5 , Lilio Hu  4   5 , Andrea Angelini  4   5 , Miriam Di Nunzio  4   5 , Edoardo Tringali  4   5 , Alessandra Cingolani  4   5 , Beatrice Claudia Marchegiani  4   5 , Angelo Rigotti  3 , Gaetano La Manna  4   5
Affiliations
Observational Study

Anti-Inflammatory Approach in Chronic Dialysis Patients with SARS-CoV-2: ATA or PMMA Dialyzers?

Gabriele Donati et al. Blood Purif. 2023.

Abstract

Introduction: High-flux hemodialysis membranes may modulate the cytokine storm of SARS-CoV-2, but their impact on chronic hemodialysis (CHD) patients is unknown. The aim of the study was the evaluation of asymmetric cellulose triacetate (ATA) and polymethylmethacrylate (PMMA) dialyzers on inflammatory markers and clinical outcomes in CHD patients with SARS-CoV-2.

Methods: A prospective, observational study on CHD patients with SARS-CoV-2 was carried out. Patients were enrolled from March 2020 to May 2021. Pre- and postdialysis C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) were determined at each session. Patients who underwent on-line hemodiafiltration (OLHDF) with a PMMA dialyzer were compared with those treated with OLHDF with a ATA dialyzer. The primary endpoint was the differences in the reduction ratio per session (RR) of CRP, PCT, IL-6, and IL-6 RR >25%.

Results: We consecutively enrolled 74 CHD patients with COVID-19, 48 were treated with ATA membrane, and 26 with PMMA. Median IL-6 RR was higher in the ATA group compared to PMMA (17.08%, IQR -9.0 to 40.0 vs. 2.95%, IQR -34.63 to 27.32). Median CRP RR was 7.77% (IQR 2.47-13.77) in the ATA group versus 4.8% (IQR -2.65 to 11.38) in the PMMA group (p = 0.0017). Median PCT-RR% was 77.38% (IQR 70.92-82.97) in ATA group versus 54.59% (IQR 42.62-63.16) in the PMMA group (p < 0.0001). A multiple logistic regression analysis with IL-6 RR >25% as the outcome including the membrane employed, pre-dialysis IL-6, CRP, PCT, and ferritin showed that ATA led to a higher probability to reach the outcome (OR 1.891, 95% CI 1.273-2.840, p = 0.0018) while higher CRP favors the risk of lower IL-6 RR values (OR 0.910, 95% CI 0.868-0.949, p ≤ 0.0001).

Conclusions: In SARS-CoV-2 CHD patients treated with OLHDF, ATA showed a better anti-inflammatory profile, regarding IL-6 RR, compared to PMMA.

Keywords: Asymmetric cellulose triacetate; COVID-19; Cytokine storm; End stage renal disease; Hemodiafiltration; Polymethylmethacrylate.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Fig. 1
Fig. 1
IL-6 RR% in ATA versus PMMA group. Data expressed as median (IQR).
Fig. 2
Fig. 2
IL-6 RR% comparison between tertiles on the basis of IL-6 pre-diaysis level in ATA (a) and in PMMA group (b). Data expressed as median (IQR).
None
See this image and copyright information in PMC

References

    1. Goffin E, Candellier A, Vart P, Noordzij M, Arnol M, Covic A, et al. COVID-19-related mortality in kidney transplant and haemodialysis patients a comparative, prospective registry-based study. Nephrol Dial Transplant. 2021 Nov;36((11)):2094–2091. - PMC - PubMed
    1. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584((7821)):430–436. - PMC - PubMed
    1. Nordio M, Reboldi G, Di Napoli A, Quintaliani G, Alberici F, Postorino M, et al. Risk factors and action thresholds for the novel coronavirus pandemic. Insights from the Italian Society of Nephrology COVID-19 Survey. J Nephrol. 2021 Apr;34((2)):325–335. - PMC - PubMed
    1. Bertrand D, Hamzaoui M, Lemée V, Lamulle J, Hanoy M, Laurent C, et al. Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients. J Am Soc Nephrol. 2021 Sep;32((9)):2147–2152. - PMC - PubMed
    1. Attias P, Sakhi H, Rieu P, Soorkia A, Assayag D, Bouhroum S, et al. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. Kidney Int. 2021 Jun;99((6)):1490–1492. - PMC - PubMed

Publication types

LinkOut - more resources